Alfasigma is the new IFAB member

The application of digital technologies in the medical field has already allowed significant improvements in the well-being of the world’s population, ensuring a considerable increase in life expectancy and quality.
To develop the full potential of Artificial Intelligence and HPC applications to the medical field, it will be necessary to create a “common ground” for the collaboration between the public and private sector in order to produce the required progress.

Alfasigma, one of the leading Italian pharmaceutical companies, is present in over 90 countries, through distributors and subsidiaries and has a workforce of around 3,000 people, R&D laboratories, and 5 production plants.
In Italy Alfasigma is a leader in the market for prescription products where, in addition to the strong focus on Gastro-Intestinal, it is present in many primary care therapeutic areas. It also produces and markets self-medication products, nutraceuticals and food supplements.

More information is available at the Alfasigma website at:

Previous Post
Net Service and IFAB together to create new synergies between research and business
Next Post
IFAB presents its projects to members
Stay updated on the latest IFAB events and projects.Subscribe to our monthly newsletter